

GLOBAL CARDIOLOGY

Editor-in-Chief: Andrew J.S. Coats, Australia

elSSN: 2975-2728

https://www.globalcardiology.info/

The Global Implementation Guidelines Initiative: how to optimize cardio-renalmetabolic care worldwide

10.4081/cardio.2025.68

Conflicts of interests

Please note that these are given with a broad consideration; however, the manuscript does not describe or discuss any pharmaceuticals or devices that might be manufactured or sold by any company including those listed below.

Fausto J. Pinto (FP), Stefan D. Anker (SDA), William T. Abraham (WTA), John J. Atherton (JJA), Javed Butler (JB), Vijay Chopra (VC), Andrew J.S. Coats (AJSC), Yann Colardelle (YC), Maria Rosa Costanzo (MRC), Veronica Dean (VD), Gerasimos Filippatos (GF), Martha Gulati (MG), Julio Rosenstock (JR), John Teerlink (JT), Subodh Verma (SV), Jose Luis Zamorano (JLZ), Yuhui Zhang (YZ), Shelley Zieroth (SZ).

FP: Speaker fees, advisory board: AstraZeneca, Abbott, Boehringer-Ingelheim.

SDA: Grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and/or lectures from Actimed, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Occlutech, Pfizer, Regeneron, Repairon, Scirent, Sensible Medical, Servier, Vectorious, and V-Wave. Named coinventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents.

JB: Consultant to Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pharmacosmos, Pharmain, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll.

VC: speaking fee from Novartis, Astra, Sanofi, Novo-Nordisk, Boehringer, Pfizer, Sun pharma, Glenmark, Mankind, Lupin, Intas, Dr. Reddy's.

YC: Employee of MedEd Global Solutions (a medical education company).

MRC: Consultant: Boehringher-Ingelheim. Member, Board of Directors, Nuwellis.

VD: Translational Medicine Academy.

GF: lecture fees and /or advisory and /or trial committee membership by Bayer, Boehringer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Ingelheim, Servier, Novartis, Impulse Dynamics, Vifor, Medtronic, Novo Nordisk.

MG: This work was supported by contracts from the National Heart, Lung, and Blood Institutes nos. N01-HV-068161, N01-HV-068162, N01-HV-068163, N01-HV-068164, grants U01 HL064829, U01 HL649141, U01 HL649241, K23 HL105787, K23 HL125941, K23 HL127262, K23HL151867, T32 HL069751, R01 HL090957, R03 AG032631, R01 HL146158, R01 HL146158-04S1, R01 HL124649, R01 HL153500, U54 AG065141, General Clinical Research Center grant MO1-RR00425 from the National Center for Research Resources, the National Center for Advancing Translational Sciences Grant UL1TR000124, Department of Defense grant PR161603 (CDMRP-DoD), and grants from the Gustavus and Louis Pfeiffer Research Foundation, Danville, NJ, The Women's Guild of Cedars-Sinai Medical Center, Los Angeles, CA, The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, PA, and QMED, Inc., Laurence Harbor, NJ, the Edythe L. Broad and the Constance Austin Women's Heart Research Fellowships, Cedars-Sinai Medical Center, Los Angeles, CA, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center, Los Angeles, CA, The Society for Women's Health Research, Washington, D.C., the Linda Joy Pollin Women's Heart Health Program, the Erika Glazer Women's Heart Health Project, the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, CA, Robert NA. Winn Diversity in Clinical Trials Career Development Award (Winn CDA), and the Anita Dann Friedman Endowment in Women's Cardiovascular Medicine & Research. This work is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute, the National Institutes of Health, or the U.S. Department of Health and Human Services. Consultant Fees/Honoraria: Esperion, Medtronic Inc, unrelated to this work.

JR: Clinical research grants from Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Carmot, Corcept, Eli Lilly and Company, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Regeneron, Pfizer, and Sanofi. Served on scientific advisory boards and received honorarium or consulting fees from Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eli Lilly and Company, Hanmi, Novo Nordisk, Oramed, Regeneron, Roche, Sanofi, Structure Therapeutics, and Zealand. Received honoraria for lectures from Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and Sanofi.

JT: Research Contracts: 3ive Labs, Angitia, Astra Zeneca, Bayer, Boehringer-Ingelheim, Cardurion, Cytokinetics, EBR Systems, Edgewise Therapeutics, Edwards, Impulse Dynamics, Kaiser Permanente, LivaNova, Medtronic, Myovant, PCORI, RECARDIO, V-Wave. Consultant: 3ive Labs, Arena, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers-Squibb, Cardurion, CorHepta, Cytokinetics, Daiichi-Sankyo, EBR Systems, Edwards, Impulse Dynamics, JuvLabs, Kaiser Permanente, Lilly, LivaNova, Medtronic, Myovant, Novartis, PCORI, Pfizer, RECARDIO, ReCor Medical, Regeneron, Reprieve, Tectonic, V-Wave, Verily, ViCardia, Windtree Therapeutics.

SV: holds a Tier 1 Canada Research Chair in Cardiovascular Surgery; and reports receiving grants and/or research support and/or speaking honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Humber River Health, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management Inc, Sanofi, and Sun Pharmaceuticals. He is the President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization.

JLZ: speaker honoraria: Bayer, Daiichi, Pfizer.

SZ: received research grant support, served on advisory boards for, or speaker engagements with

AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cytokinetics, Eli Lilly, GSK, Janssen, Medtronic, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Salubrisbio, Servier and Vifor Pharma; and serves on a clinical trial committee or as a national lead for studies sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis and Pfizer. Non industry: Canadian Medical and Surgical KT Group, CCS, CHFS, Charite, EOCI, Liv, Medscape, Ology, PACECME, Radcliffe, Reach MD, Translational Medicine Academy.

WTA, JJA, AJSC, YZ: report no conflicts of interest.